The company utilizes raw materials to manufacture its product candidates, including zumilokibart, APG990, APG333, and APG808. It maintains or plans to maintain sufficient manufacturing capacity and clinical supply to support its clinical trials. To address supply chain risks, particularly in relation to the BIOSECURE Act, the company is identifying and selecting additional suppliers based in the U.S. and EU for contract development, manufacturing, testing, and storage. It monitors geopolitical risks and implements mitigation strategies and redundancies as necessary. Key suppliers include WuXi Biologics and Samsung Biologics.
Apogee Therapeutics Inc's Comment on Supply Chain
The company utilizes raw materials to manufacture its product candidates, including zumilokibart, APG990, APG333, and APG808. It maintains or plans to maintain sufficient manufacturing capacity and clinical supply to support its clinical trials. To address supply chain risks, particularly in relation to the BIOSECURE Act, the company is identifying and selecting additional suppliers based in the U.S. and EU for contract development, manufacturing, testing, and storage. It monitors geopolitical risks and implements mitigation strategies and redundancies as necessary. Key suppliers include WuXi Biologics and Samsung Biologics.
Sources:
Apogee Therapeutics Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Apogee Therapeutics Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
